东宝生物
(300239)
| 流通市值：25.57亿 | | | 总市值：28.97亿 |
| 流通股本：5.24亿 | | | 总股本：5.94亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 241,778,598.22 | 974,512,217.68 | 734,671,103.09 | 520,698,643.54 |
| 营业收入 | 241,778,598.22 | 974,512,217.68 | 734,671,103.09 | 520,698,643.54 |
| 二、营业总成本 | 209,838,876.06 | 834,255,884.59 | 618,064,708.07 | 439,435,410.63 |
| 营业成本 | 191,383,244.9 | 725,695,459.9 | 538,072,682.27 | 384,261,635.11 |
| 税金及附加 | 2,479,134.28 | 12,578,092.49 | 9,649,008.08 | 7,002,352.69 |
| 销售费用 | 3,627,263.9 | 19,612,333.51 | 13,832,950.66 | 9,319,435.69 |
| 管理费用 | 10,003,077.61 | 51,522,312.4 | 37,130,253.88 | 25,889,331.02 |
| 研发费用 | 4,046,567.55 | 26,100,645.39 | 19,739,946.75 | 12,948,212.64 |
| 财务费用 | -1,700,412.18 | -1,252,959.1 | -360,133.57 | 14,443.48 |
| 其中:利息费用 | 631,693.86 | 5,140,212.77 | 4,121,449.46 | 2,857,910 |
| 其中:利息收入 | 2,180,638.86 | 6,367,697.87 | 4,409,565.22 | 2,775,032.07 |
| 加:投资收益 | -1,158,672.48 | -4,329,558.16 | -3,647,909.07 | -2,385,456.84 |
| 资产处置收益 | -279,378.71 | 76,746.62 | 28,498.05 | 28,498.05 |
| 资产减值损失(新) | 135,514.67 | -1,448,662.74 | 19,226.86 | 177,310.5 |
| 信用减值损失(新) | 62,020.94 | -1,556,406.64 | -510,785.46 | 44,132.27 |
| 其他收益 | 2,868,307.89 | 10,880,743.05 | 6,437,432.48 | 2,980,385.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 33,567,514.47 | 143,879,195.22 | 118,932,857.88 | 82,108,102.53 |
| 加:营业外收入 | 33,136 | 1,619,462.04 | 495,058.31 | 36,960.5 |
| 减:营业外支出 | 875,742.61 | 1,006,068.53 | 425,242.42 | 227,936.48 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 32,724,907.86 | 144,492,588.73 | 119,002,673.77 | 81,917,126.55 |
| 减:所得税费用 | 4,643,140.22 | 17,121,471.22 | 17,070,063.98 | 11,324,317.21 |
| 六、净利润 | 28,081,767.64 | 127,371,117.51 | 101,932,609.79 | 70,592,809.34 |
| 持续经营净利润 | 28,081,767.64 | 127,371,117.51 | 101,932,609.79 | 70,592,809.34 |
| 归属于母公司股东的净利润 | 25,961,526.88 | 119,885,372.42 | 95,261,690.05 | 65,004,093.43 |
| 少数股东损益 | 2,120,240.76 | 7,485,745.09 | 6,670,919.74 | 5,588,715.91 |
| (一)基本每股收益 | 0.04 | 0.2 | 0.16 | 0.11 |
| (二)稀释每股收益 | 0.04 | 0.2 | 0.16 | 0.11 |
| 九、综合收益总额 | 28,081,767.64 | 127,371,117.51 | 101,932,609.79 | 70,592,809.34 |
| 归属于母公司股东的综合收益总额 | 25,961,526.88 | 119,885,372.42 | 95,261,690.05 | 65,004,093.43 |
| 归属于少数股东的综合收益总额 | 2,120,240.76 | 7,485,745.09 | 6,670,919.74 | 5,588,715.91 |
| 公告日期 | 2024-04-24 | 2024-04-24 | 2023-10-30 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |